New hope for prostate cancer: drug combo before surgery shows promise

NCT ID NCT06627530

Ongoing Disease control Sponsor: Brazilian Clinical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate cancer. The main goal is to see if the combination leads to less cancer remaining in the surgical specimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

BP - A Beneficência Portuguesa de São Paulo

São Paulo, São Paulo, 01323001, Brazil
Hospital Ophir Loyola

Belém, Pará, 66063-240, Brazil
Hospital São Marcos

Teresina, Piauí, 64001-280, Brazil
Hospital Universitário Pedro Ernesto

Rio de Janeiro, Rio de Janeiro, 20551-030, Brazil
Hospital de Clínicas Ijuí

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Santa Casa de Misericórdia de Feira de Santana

Feira de Santana, Estado de Bahia, 44001-032, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.